Navigation Links
Celator(R) Pharmaceuticals Enrolls First Patient in Its Phase 2 Study of CPX-351 in Acute Myeloid Leukemia in First Relapse
Date:3/10/2009

The study is supported by The Leukemia & Lymphoma Society(R)

PRINCETON, N.J., March 10 /PRNewswire/ -- Celator Pharmaceuticals today announced that the first patient has been treated in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus intensive salvage therapy in adult patients (up to 60 years old) with acute myeloid leukemia in first relapse. As previously announced, the study is being supported through a partnership with The Leukemia & Lymphoma Society (LLS).

The first patient was enrolled by Maureen Cooper, M.D., at St. Francis Hospital in Beech Grove, Indiana. "We are pleased to be participating in this study and eager to collect additional clinical evidence demonstrating the benefit of delivering and maintaining a synergistic ratio of these two widely used drugs for the treatment of AML," said Dr. Cooper.

"CPX-351 represents a unique approach to enhancing the clinical benefit of the two most active drugs used in the treatment of patients with AML," said Jonathan Kolitz, M.D., Director of the Leukemia Service at North Shore University Hospital and lead investigator for the study. "There is no standard of care established for patients in first relapse. We expect that this study will build on the promising results initially obtained in this patient population in the Phase 1 study and provide additional confirmation of the clinical benefit of CPX-351."

The study (Protocol CLTR0308-205) will enroll up to 120 patients between the ages of 18 and 60 who have pathological confirmation of relapsed AML after an initial complete response to prior therapy lasting at least one month. Patients will be randomized (2:1) to receive either CPX-351 (100u/m2; Days 1, 3, 5) or one of several control arm regimens, including high dose cytarabine with or without daunorubicin; conventional "7+3" (cytarabine/daunorubicin reg
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals
2. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
3. Celator(R) Pharmaceuticals To Present at Biotech Showcase 2009
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... A University of Iowa study reveals significant disparities ... for completing substance abuse treatment programs. Moreover, these ... , "Our findings suggest that for most states ... professor of psychiatry and biostatistics. "There are strong ... able to complete substance abuse treatment programs successfully, ...
(Date:6/19/2013)... percent of Americans are on at least one ... Mayo Clinic researchers say. Antibiotics, antidepressants and painkilling ... Twenty percent of patients are on five or ... online in the journal Mayo Clinic Proceedings ... of Dr. Jennifer St. Sauver talking about the ...
(Date:6/19/2013)... pharmaceutical companies, along with the Japanese government and ... commitment to bolster Japan,s contribution to global health ... Fund), at a press conference held as a ... on African Development (TICAD V). , Representatives from ... of Health, Labour and Welfare, the Ministry of ...
(Date:6/19/2013)... PREFERRED Therapy Providers, Inc. (PREFERRED) has ... to offer a new Medicare Advantage Plan for PREFERRED’s ... and Mohave, Arizona counties. The agreement takes effect in ... 1, 2013 and Maricopa and Pima counties will become ... parent company of WellCare of Arizona has Medicare Advantage ...
(Date:6/19/2013)... June 19, 2013 Guests at the Residence ... and wise even if they don’t go to bed or ... some early thought. , Crafty travelers will ... take advantage of the pet-friendly Scottsdale Paradise Valley hotel’s Book ... With at least 14 days advance notice, guests can enjoy ...
Breaking Medicine News(10 mins):Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 3Health News:PREFERRED Therapy Providers, Inc. and WellCare of Arizona Finalize Their Agreement to Offer Medicare Advantage Plan to PREFERRED's Arizona Provider Network 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4
... , SATURDAY, Nov. 19 (HealthDay News) -- Eating certain ... white after you,ve used an at-home whitening kit or ... individuals who have had good results with either dentist-directed ... to keep the teeth white after bleaching," Dr. Raymond ...
... 18 (HealthDay News) -- A new study finds that many ... seat belt when they ride in cars -- a practice ... at a 2007 National Highway Traffic Safety Administration survey of ... their 4- to 9-year-old passengers use seat belts and more ...
... - IBM,s Watson computing system broke new ground earlier this ... Jeopardy! game show. Now, The Scripps Research Institute is hoping ... health with part of the prize money from that tournament: ... the public,s help. To that end, Scripps Research ...
... , FRIDAY, Nov. 18 (HealthDay News) -- Those in the ... U.S. government health experts now encourage Americans to ... new system assigns no points to nearly all fruits and ... what,s the big deal? Why is it so important to ...
... Nov. 18 (HealthDay News) -- Hispanics are the focus of ... says the American Podiatric Medical Association (APMA). Hispanics are ... diabetes, which can result in foot ulcers and lower limb ... lack of exercise and genetics, risk factors that are especially ...
... -- Researchers at Wake Forest Baptist Medical Center and ... up for a research project aimed at advancing the ... (PTSD) and traumatic brain injury (TBI). "PTSD ... coming home from Iraq and Afghanistan," said Dwayne W. ...
Cached Medicine News:Health News:Watch What You Eat After Teeth-Whitening, Expert Says 2Health News:Ill-Fitting Children's Seat Belts Common in U.S., Study Finds 2Health News:Jeopardy! winnings spur IBM and Scripps Research Institute collaboration to fight against malaria 2Health News:Jeopardy! winnings spur IBM and Scripps Research Institute collaboration to fight against malaria 3Health News:For Nutritional Punch, You Can't Beat Plant-Based Foods 2Health News:For Nutritional Punch, You Can't Beat Plant-Based Foods 3Health News:For Nutritional Punch, You Can't Beat Plant-Based Foods 4Health News:Hope on the horizon for patients with post-traumatic stress disorder 2Health News:Hope on the horizon for patients with post-traumatic stress disorder 3
(Date:6/19/2013)... CARLSBAD, Calif. , June 19, 2013 /PRNewswire/ ... ) today announces a licensing agreement granting Suzhou ... develop and manufacture siRNA therapeutics in ... technology.  Ribo will formulate proprietary siRNA molecules in ... platform designed to address human diseases with high ...
(Date:6/19/2013)... Calif. , June 19, 2013 ... management solutions, introduced the next-generation of its ... which allows health plans to provide their employer ... populations, health factors, medical and prescription drug claims, ... (Logo: http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) ...
(Date:6/19/2013)... 2013 Specialty Coating Systems ... von SCS microRESIST™, einer antimikrobiellen Parylene-Technologie, ... mit Parylene gelungen ist. SCS microRESIST ... mit antimikrobiellen Eigenschaften und erlaubt damit ... beschichteten medizinischen Geräten. (Logo: ...
Breaking Medicine Technology:Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2
... winner Gloria Gaynor -- whose hit songs have captivated the ... Orlando@50+ National Event & Expo to raise awareness ... potentially debilitating condition. This high profile event, with an estimated ... at the Orange County Convention Center in Orlando, FL. ...
... Biotechnology, Inc. (Pink Sheets: ACEL ) ... by the National Institute of Allergy and Infectious ... our lead compounds outperformed market leader Roche,s drug ... (the gold standard) for Cytomegalovirus (CMV) disease. Additionally, ...
Cached Medicine Technology:Gloria Gaynor to Appear at AARP's Orlando@50+ National Event & Expo 2New Discovery Targets Cytomegalovirus (CMV) 2New Discovery Targets Cytomegalovirus (CMV) 3New Discovery Targets Cytomegalovirus (CMV) 4
... Ossur range of prefabricated foot and ankle ... - from ankle instability to foot malalignment. ... designs and energy-return technology., ,Age is ... ankle foot orthoses provide a measure of ...
... The Stabilizing Ankle support features ... which lock the calcaneus into ... eversion and inversion. The full-circumference ... and stability. Ideal for chronic ...
... Walker Pediatric Boot is the ... boot that offers superior comfort ... two sizes are offered thus ... will fit left or right, ...
... The Bledsoe PTB Boot is ... alternative to casting for the mid-tibia ... providing patella tendon bearing support. The ... designed for range of motion from ...
Medicine Products: